Bristol Myers strikes $13B MyoKardia buyout to gain heart drug
Bristol Myers Squibb has struck a deal to acquire MyoKardia for $13.1 billion. The all-cash takeover will see Bristol Myers pay a 61% premium to MyoKardia’s closing price on Friday to secure a heart disease drug that is nearing a filing for approval.